Posters
Read research from Cogstate scientists as presented at industry conferences.
Central monitoring of rater performance and characteristics of efficacy assessments in the TRAILBLAZER-ALZ 2 study
Presented at ADPD 2024
TRAILBLAZER-ALZ 2 (NCT04437511) is a phase 3 study that evaluated the safety and efficacy of donanemab in individuals with early symptomatic Alzheimer’s disease (AD) with confirmed amyloid presence and specified tau levels. Although most clinical trials […]
View PosterInvestigating Cognitive Practice Effects in Schizophrenia Using Repeated Assessment at Short Retest Intervals Prior to Randomization in a Clinical Trial
Presented at ISCTM 2024
In clinical trials of schizophrenia, improvement in cognition in both placebo and treatment arms is common. Such improvementmay impact the ability of clinical trials to identify any cognitive benefits of new pharmacotherapies (Keefe et al., 2011). […]
View PosterRemote Assessment of Cognition with the Unsupervised Version of the Cogstate Brief Battery: Association of Composite Endpoints with Alzheimer’s Disease Biomarkers
Presented at ADPD 2024
In people at risk of Alzheimer’s disease (AD), access to cognitive assessment can be increased through application of internet-based registries. While cognitive data collected remotely from registries provides only limited information to support clinical decision making, it can be linked to specialist management clinics which allow for analyses and more comprehensive follow-up. The Cogstate Brief Battery (CBB) has been optimized for unsupervised and remote use in registries with CBB outcomes shown to be sensitive to dementia risk factors such as carriage of the Apoe4 allele, higher levels of cerebral vascular risk factors, and sleep disorders. Furthermore, new analyses of data from the CBB has indicated that multiple composite scores are sensitive to AD related cognitive impairment.
View PosterA biomarker to aid Alzheimer’s disease staging: sTREM2 is decreased in Amyloid positive/Tau negative, yet increased once Tau aggregates leading to increased cognitive decline
Presented at CTAD 2023
The development of high accuracy biofluid assays now allows the use of fluid-based biomarkers into Alzheimer’s disease (AD) clinical pathological models. Integration of amyloid and tau biomarkers into AD models has confirmed the centrality of amyloid and tau biology in AD-related neurodegeneration, and to the expression of AD symptoms, such as cognitive decline, and clinical disease progression. AD disease models are now seeking to exploit and use validated fluid biomarkers of other neurodegenerative processes, such as neuroinflammation, to increase understanding of AD beyond amyloid and tau. The soluble triggering receptor expressed on myeloid cells 2 (sTREM2) can be measured in the CSF, providing an opportunity to determine the extent to which measurement of neuroinflammation can add information to amyloid, tau and neurodegeneration based (ATN) models of AD related cognitive decline.
View PosterThe effect of APOE ε4 status on subregional basal forebrain atrophy in Alzheimer’s disease
Presented at CTAD 2023
Dysfunction of the cholinergic BF system and deposition of amyloid-β (Aβ) are early pathological features in Alzheimer’s disease (AD). The Apolipoprotein E (APOE) ε4 allele is the strongest genetic risk factor for late-onset AD and exacerbates Aβ accumulation and cognitive decline. Objective: To investigate the effects of APOE ε4 carriage on rates of volume loss in basal forebrain (BF) subregions among older individuals.
View PosterDo Alzheimer’s Risk Genes also Predict Cognitive Decline?
Presented at CTAD 2023
It is the priority of candidate Alzheimer’s disease (AD) therapeutics to slow progression and preserve quality of life for those on the disease trajectory. To effectively demonstrate and measure this, randomised controlled trials would ideally control for factors that alter rates of cognitive decline independent of the intervention under study. Genome wide association studies (GWAS) have now implicated >40 genes that appear to be associated with elevated disease risk1-3. The pathways involved have shed light on possible underlying disease mechanisms. Could these (or other) genes help to predict rates of cognitive decline?
View PosterA comparison of machine learning based-composite cognitive test scores to track cognitive decline in early stages of Alzheimer’s disease dementia: ADOPIC study
Presented at AAIC 2023
Clinical trials for early dementia require cognitive measures that capture disease progression across multiple domains. Precise cognitive assessment is crucial for tracking early Alzheimer’s disease (AD) dementia. Current cognitive endpoints, like the Preclinical Alzheimer Cognitive Composite (PACC), average standardized change from baseline scores. The use of a machine learning (ML)-based cognitive composite score, computed through principal component analysis (PCA), enhanced the ability to track cognitive decline in individuals with mild cognitive impairment (MCI) progressors compared to PACC, while remaining comparable in cognitively unimpaired (CU) progressors
View PosterAdaptation and Modification of Digital Cognitive Assessments for Smartphone-based and Unsupervised Conduct
Presented at AAIC 2023
Remote and decentralized methods offer advantages in clinical trials, such as reducing burden, improving recruitment, and enabling high-frequency assessment. Smartphone-based cognitive assessment, particularly in BYOD trials, allows for novel designs. However, understanding potential errors from delivery platforms (e.g., smartphones vs. computers) is crucial. Cogstate Brief Battery (CBB) data from young adults in a crossover study (n=60) and a large study (n=35,000) of unsupervised smartphone-based assessments were utilized to gather insights into digital assessments in remote settings.
View PosterAmyloid-β and monocytes in Alzheimer’s disease
Presented at AAIC 2023
This study explores whether human monocyte-derived macrophages can eliminate brain Aβ and migrate to the periphery for antigen presentation, addressing this puzzle.
View PosterCognitive function in older adults with hearing loss; outcomes for treated versus untreated groups at 3-year follow-up.
Presented at AAIC 2023
Cognition remained stable for hearing aid users but declined for non-users at a 3-year follow-up. Hearing aid treatment may delay cognitive decline. Referral for hearing screening and rehabilitation could help minimize cognitive decline in older adults. Hearing loss, affecting 70% of adults aged ≥70, is independently associated with cognitive decline and considered a modifiable risk factor for dementia. Limited evidence exists on the impact of hearing aid use on cognition in older adults beyond 6-12 months, highlighting the need for further objective studies. This longitudinal cohort study compared outcomes of new hearing aid users with those without over a 3-year period
View Poster